{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "CBT",
      "antidepressant",
      "anxiety",
      "benzodiazepine",
      "pseudo-resistance",
      "refractory"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "Una proporci\u00f3n considerable de pacientes psiqui\u00e1tricos buscar\u00e1 evaluaci\u00f3n cl\u00ednica y tratamiento para s\u00edntomas ansiosos que se consideran refractarios al tratamiento. Esta aparente falta de respuesta puede deberse a una \u201cpseudo-resistencia\u201d (un fracaso al haber recibido y adherido a un tratamiento efectivo y reconocido o a tratamientos para su condici\u00f3n) o a una verdadera \u201cresistencia terap\u00e9utica\u201d. La pseudo-resistencia puede deberse a errores cl\u00ednicos en la selecci\u00f3n y administraci\u00f3n de un tratamiento efectivamente apropiado, o a la falta de adherencia del paciente durante un per\u00edodo de tratamiento. La verdadera resistencia terap\u00e9utica puede deberse a factores ansiog\u00e9nicos ex\u00f3genos no reconocidos (como exceso de cafe\u00edna, privaci\u00f3n de sue\u00f1o, uso de alcohol o marihuana) o a diagn\u00f3sticos incorrectos (como enfermedad bipolar at\u00edpica, abuso oculto de sustancias, trastorno por d\u00e9ficit atencional con hiperactividad). Cuando se han descartado los factores anteriores, el tratamiento debe enfocarse en la combinaci\u00f3n de medicamentos efectivos y terapia cognitivo conductual, combinaci\u00f3n de varios f\u00e1rmacos (aumentaci\u00f3n) o el empleo de nuevos medicamentos o psicoterapias para la ansiedad que no se indican habitualmente como tratamientos de primera l\u00ednea basados en la evidencia."
      ]
    },
    {
      "AbstractText": [
        "Une proportion importante de patients psychiatriques sollicite un traitement et une \u00e9valuation clinique pour des sympt\u00f4mes anxieux qui seraient r\u00e9fractaires au traitement. Ce manque de r\u00e9ponse apparent est d\u00fb soit \u00e0 une \u00ab pseudo-r\u00e9sistance \u00bb (l'absence de prescription ou d'observance d'un traitement reconnu et efficace ou \u00e0 un traitement adapt\u00e9 \u00e0 leur pathologie) soit \u00e0 une v\u00e9ritable \u00ab r\u00e9sistance au traitement \u00bb. La pseudo-r\u00e9sistance peut \u00eatre due \u00e0 une erreur du m\u00e9decin dans le choix et la d\u00e9livrance d'un traitement appropri\u00e9 efficace, ou \u00e0 la non-observance du patient au traitement. Une v\u00e9ritable r\u00e9sistance au traitement peut \u00eatre due \u00e0 des facteurs anxiog\u00e8nes exog\u00e8nes non reconnus (par exemple surconsommation de caf\u00e9ine, privation de sommeil, consommation d'alcool ou de marijuana) ou \u00e0 un mauvais diagnostic (par exemple maladie bipolaire atypique, toxicomanie cach\u00e9e, trouble d\u00e9ficit de l'attention avec hyperactivit\u00e9). Une fois ces facteurs \u00e9limin\u00e9s, le traitement doit se focaliser sur l'association de m\u00e9dicaments efficaces et de th\u00e9rapie cognitive comportementale, sur l'association de plusieurs m\u00e9dicaments (potentialisation), ou \u00e0 l'aide de nouveaux traitements ou psychoth\u00e9rapies non indiqu\u00e9s formellement en premi\u00e8re ligne pour l'anxi\u00e9t\u00e9."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "26246793",
  "DateCompleted": {
    "Year": "2016",
    "Month": "04",
    "Day": "29"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "12",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1958-5969",
      "JournalIssue": {
        "Volume": "17",
        "Issue": "2",
        "PubDate": {
          "Year": "2015",
          "Month": "Jun"
        }
      },
      "Title": "Dialogues in clinical neuroscience",
      "ISOAbbreviation": "Dialogues Clin Neurosci"
    },
    "ArticleTitle": "Treatment-refractory anxiety; definition, risk factors, and treatment challenges.",
    "Pagination": {
      "StartPage": "191",
      "EndPage": "206",
      "MedlinePgn": "191-206"
    },
    "Abstract": {
      "AbstractText": [
        "A sizable proportion of psychiatric patients will seek clinical evaluation and treatment for anxiety symptoms reportedly refractory to treatment. This apparent lack of response is either due to \"pseudo-resistance\" (a failure to have received and adhered to a recognized and effective treatment or treatments for their condition) or to true \"treatment resistance.\" Pseudo-resistance can be due to clinician errors in selecting and delivering an appropriate treatment effectively, or to patient nonadherence to a course of treatment. True treatment resistance can be due to unrecognized exogenous anxiogenic factors (eg, caffeine overuse, sleep deprivation, use of alcohol or marijuana) or an incorrect diagnosis (eg, atypical bipolar illness, occult substance abuse, attention deficit-hyperactivity disorder). Once the above factors are eliminated, treatment should focus on combining effective medications and cognitive behavioral therapy, combining several medications (augmentation), or employing novel medications or psychotherapies not typically indicated as first-line evidence-based anxiety treatments."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Professor of Psychiatry, University of Washington School of Medicine, Harborview Medical Center, Seattle, Washington, USA; Founding Partner, Psychiatric Medicine Associates, Seattle, Wash-ington, USA."
          }
        ],
        "LastName": "Roy-Byrne",
        "ForeName": "Peter",
        "Initials": "P"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Dialogues Clin Neurosci",
    "NlmUniqueID": "101238198",
    "ISSNLinking": "1294-8322"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Anxiety Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Anti-Anxiety Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "psychology",
        "therapy"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Cognitive Behavioral Therapy"
    },
    {
      "QualifierName": [
        "statistics & numerical data"
      ],
      "DescriptorName": "Databases, Bibliographic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}